DCTH - Delcath Systems Inc logo

Delcath Systems Inc

DCTH

Delcath Systems develops treatment solutions for primary and metastatic liver cancers, focusing on its HEPZATO KIT for administering high-dose chemotherapy directly to the liver. The company markets the CHEMOSAT system in Europe for similar applications.

⚕️ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 20 years ago →$3,929today

Score Overview

1 Year
Score
Net Growth-80.30%
Net TrendShrank
Net Income Consistency—
Rev Growth11.95%
Rev TrendGrew
Revenue Consistency—
5 Years
Score5.6
Net Growth102.07%
Net Trend40%
Net Income Consistency—
Rev Growth26x
Rev Trend60%
Revenue Consistency—
All Time
Score
Net Growth102.77%
Net Trend38%
Net Income Consistency
Rev Growth28x
Rev Trend63%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Delcath Systems Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. DCTH does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 14.42—
1 Year2025-10-23
$ 10.3838.92%
5 Years2021-10-22
$ 10.0643.34%
10 Years2016-10-21
$ 2.326x
20 Years2006-10-23
$ 3.67292.92%
All Time2018-05-29
$ 2.1K-99.31%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 95M$ 532K$ 95M
2025$ 85M$ 2M$ 91M
2024$ 37M-$ 26M$ 53M
2023$ 2M-$ 47M$ 32M
2022$ 2M-$ 36M$ 7M
2021$ 3M-$ 25M$ 22M
2020$ 1M-$ 24M$ 28M
2019$ 1M-$ 8M$ 10M
IPO2018$ 3M-$ 19M$ 2M
DCTH - Delcath Systems Inc logo

Delcath Systems Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 1M to $ 85M and net income went from -$ 24M to $ 2M. Revenue increased in 3 of those 5 years; net income in 2.

Delcath Systems Inc currently holds a 5-year HDB Score of 5.6 out of 10. How the HDB Score is calculated.

Membership

Explore DCTH with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies